A detailed history of Fin Trust Capital Advisors, LLC transactions in Genmab A/S stock. As of the latest transaction made, Fin Trust Capital Advisors, LLC holds 196 shares of GMAB stock, worth $4,033. This represents 0.0% of its overall portfolio holdings.

Number of Shares
196
Previous 233 15.88%
Holding current value
$4,033
Previous $5,000 20.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

SELL
$23.84 - $28.48 $882 - $1,053
-37 Reduced 15.88%
196 $4,000
Q2 2024

Jul 24, 2024

BUY
$25.13 - $30.27 $929 - $1,119
37 Added 18.88%
233 $5,000
Q1 2024

May 02, 2024

BUY
$26.43 - $32.77 $5,180 - $6,422
196 New
196 $5,000
Q3 2023

Oct 24, 2023

BUY
$35.27 - $42.24 $12,838 - $15,375
364 New
364 $12,000
Q2 2020

Aug 14, 2020

SELL
$20.05 - $33.89 $3,308 - $5,591
-165 Closed
0 $0
Q3 2019

Oct 29, 2019

BUY
$18.0 - $21.38 $2,970 - $3,527
165 New
165 $3,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.5B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Fin Trust Capital Advisors, LLC Portfolio

Follow Fin Trust Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fin Trust Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fin Trust Capital Advisors, LLC with notifications on news.